---
schema_version: "secwatch.filing_event.v1"
accession: "0000879407-25-000027"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T17:10:58.363481+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arrowhead FY2025 revenue $829M on milestones; FDA approves first drug REDEMPLO

## Summary
- Revenue $829.4M in FY2025, up from $3.6M, driven by Novartis and Sarepta milestone payments.
- FDA approved REDEMPLO (plozasiran) for FCS—first approved siRNA for the rare disease; self-administered quarterly.
- Novartis licensing agreement for ARO-SNCA: $200M upfront, up to $2B milestones, low double-digit royalties.
- Sarepta paid $300M milestones; $100M settled with cash and Arrowhead stock buyback at $18.79 per share.
- Net loss attributable to Arrowhead: ($1.6M) vs ($599M) prior year; cash resources $919.4M.

## SEC filing metadata
- accession: 0000879407-25-000027
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000087940725000027/0000879407-25-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000087940725000027/arwr-20251125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879407-25-000027
- JSON: https://secwatch.observer/filing/0000879407-25-000027.json
- Plain text: https://secwatch.observer/filing/0000879407-25-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.